Symbol="CUE"
AssetType="Common Stock"
Name="Cue Biopharma"
Description="Cue Biopharma, Inc., a clinical-stage biopharmaceutical company, develops biological drugs for the selective modulation of the human immune system to treat a variety of cancers, chronic infectious diseases, and autoimmune disorders. The company is headquartered in Cambridge, Massachusetts."
CIK="1645460"
Exchange="NASDAQ"
Currency="USD"
Country="USA"
Sector="LIFE SCIENCES"
Industry="PHARMACEUTICAL PREPARATIONS"
Address="21 ERIE STREET, CAMBRIDGE, MA, US"
FiscalYearEnd="December"
LatestQuarter="2023-03-31"
MarketCapitalization="181348000"
EBITDA="-51738528"
PERatio="None"
PEGRatio="None"
BookValue="1.274"
DividendPerShare="0"
DividendYield="0"
EPS="-1.26"
RevenuePerShareTTM="0.011"
ProfitMargin="0"
OperatingMarginTTM="-121.8"
ReturnOnAssetsTTM="-0.382"
ReturnOnEquityTTM="-0.867"
RevenueTTM="432230"
GrossProfitTTM="1245200"
DilutedEPSTTM="-1.26"
QuarterlyEarningsGrowthYOY="0"
QuarterlyRevenueGrowthYOY="-0.813"
AnalystTargetPrice="10"
TrailingPE="-"
ForwardPE="-"
PriceToSalesRatioTTM="13.03"
PriceToBookRatio="2.501"
EVToRevenue="9.35"
EVToEBITDA="-1.9"
Beta="1.982"
num_52WeekHigh="5.12"
num_52WeekLow="2.18"
num_50DayMovingAverage="4.049"
num_200DayMovingAverage="3.447"
SharesOutstanding="43178200"
DividendDate="None"
ExDividendDate="None"
symbol="CUE"
open="4.29"
high="4.34"
low="4.05"
price="4.20"
volume="404149.00"
latest_trading_day="2023-07-21"
previous_close="4.28"
change="-0.08"
change_percent="-1.8692%"
aroon_positive_momentum_days="0"
aroon_negative_momentum_days="38"
trend_strength="Absent or Weak Trend"
buying_signal="Weak Sell Signal"
volume_analysis="Target Volume"
value_analysis="Expected Range"
Aroon_change="FALSE"
Aroon_momentum="62"
Volume_recent_avg="350428"
Change_recent_avg="-0.01"
Delta_recent_avg="0.27"
Variance_recent_avg="0.13"
Change_ratio_recent_avg="-0.32"
RSI_change="FALSE"
ADX_change="FALSE"

event="FALSE"
Aroon_signal="negative"
Aroon_change="FALSE"
Aroon_momentum_positive="62"
Aroon_momentum_negative="38"
image_negative_thumbnail_id_1="137"
image_negative_url_1="https://hehge.com/wp-content/uploads/sites/16/2023/05/MI_Finance_Negative_Landscape_0039.jpeg"
image_negative_thumbnail_id_2="138"
image_negative_url_2="https://hehge.com/wp-content/uploads/sites/16/2023/05/MI_Finance_Negative_Landscape_0038.jpeg"
image_neutral_thumbnail_id_1="580"
image_neutral_url_1="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Neutral_Landscape_0019.jpeg"
image_neutral_thumbnail_id_2="536"
image_neutral_url_2="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Neutral_Landscape_0063.jpeg"
image_positive_thumbnail_id_1="1002"
image_positive_url_1="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Positive_Landscape_0164.jpeg"
image_positive_thumbnail_id_2="669"
image_positive_url_2="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Positive_Landscape_0039.jpeg"
image_professor_thumbnail_id_1="1189"
image_professor_url_1="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Professor_Landscape_0023.jpeg"
image_professor_thumbnail_id_2="1174"
image_professor_url_2="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Professor_Landscape_0008.jpeg"
